Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Abzena's Antitope subsidiary to share in Eurostars grant

A consortium of which Abzena subsidiary Antitope is a part has been awarded a €1.9mln grant under the Eurostars programme.
Abzena's Antitope subsidiary to share in Eurostars grant
The consortium is developing a novel treatment for clotting disorders

Abzena (LON:ABZA) said a consortium of which its Antitope subsidiary is a part has been awarded a €1.9mln grant under the Eurostars programme.

Other members of the consortium are: Prothix BV; Aristi Biotech BV; the University Medical Center Utrecht; and GenOnway.

The consortium is developing a novel treatment for clotting disorders, targeting anti-thrombin III, a protein that inhibits blood clotting. The novel antibody has the potential to both prevent and treat bleeding in patients with disorders such as haemophilia.

Neil Butt, vice president of Business Development at Abzena, said: "Applying our Composite Human Antibody technology to this novel product will help produce a less immunogenic version, giving it a greater chance of improving the lives of patients."

Antitope provides immunogenicity assessment, protein engineering to create humanised antibodies and de-immunised therapeutic proteins, and cell line development for manufacture.

The Eurostars Programme is a European joint programme dedicated to giving a leg-up to small-to-medium sized research & development companies.

Shares in Abzena were up 1.8% at 56p in morning trade.

John-H.jpg
Why Invest In Abzena plc? Read More Here

Register here to be notified of future ABZA Company articles
View full ABZA profile View Profile

Abzena plc Timeline

Related Articles

Blood testing
February 13 2017
Identifying cancer cells early is a key part of combatting the disease, and ANGLE's Parsortix device looks to be developing into a key ally.
shutterstock_216375733.jpg
January 24 2017
At the moment, the healthcare firm M Pharma is a work in progress
Bankroll.jpg
March 01 2017
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use